Business
NANOBIOTIX Statement Regarding Recent Media Speculation
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over. Nanobiotix states that, to the best of its knowledge, there is no such intent
About this update from Nanobiotix Sa
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eJ7NkIHzztwPinGRQcbZqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over.","length":422,"tagName":"p"},{"type":"text","content":"Nanobiotix states that, to the best of its knowledge, there is no such intention to acquire control of the Company, and no process or assessment is being conducted toward that end. Additionally, the Company has identified factual inaccuracies in this media report which are not consistent with the Company’s most recent public disclosures.","length":339,"tagName":"p"},{"type":"text","content":"About NANOBIOTIX","length":16,"tagName":"p"},{"type":"text","content":"Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.","length":384,"tagName":"p"},{"type":"text","content":"Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.","length":284,"tagName":"p"},{"type":"text","content":"Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) ...